Reports Q2 revenue $91.23B, consensus $91.5B. “We have many points of differentiation that position us to win now and into the future. Our innovation is accelerating more transparent pharmacy reimbursement models, increasing the use of biosimilars, and providing better patient outcomes through our connected health care delivery assets. Our integrated model and our strategy are enabling us to execute in a challenging environment and we are delivering the value our customers demand. We are taking action today to ensure we make the most of our many opportunities, including leadership changes in the Health Care Benefits segment.” -Karen S. Lynch, CVS Health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Options Volatility and Implied Earnings Moves This Week, August 05 – August 09, 2024
- CVS Earnings this Week: How Will it Perform?
- Phathom Pharmaceuticals announces VOQUEZNA added to CVS Caremark formularies
- CVS Health call volume above normal and directionally bullish
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 22, 2024
Questions or Comments about the article? Write to editor@tipranks.com